interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Maralixibat Chloride

Generic competition · all medicines · read 12 November 2026

Is there a generic of Maralixibat Chloride, and who makes it?

Maralixibat Chloride appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Maralixibat Chloride2 dosage-form groups in the Orange Book
0generic makers listed
  1. Maralixibat Chloride appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Livmarli. No generic is listed as marketed.

20202025203020352040204501brand 2025data datePatent 11260053 listed to expire 26 May 2031Patent 11376251 listed to expire 26 October 2032Patent 11229661 listed to expire 26 October 2032Patent 10512657 listed to expire 26 October 2032Patent 12350267 listed to expire 26 October 2032Patent 11497745 listed to expire 12 February 2040Patent 11229647 listed to expire 12 February 2040Patent 12296050 listed to expire 5 October 2043Exclusivity I-938 to 13 March 2027
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 13 March 2027Exclusivity I-938 Livmarli
  • 26 May 2031Patent 11260053
  • 26 October 2032Patent 11376251
  • 26 October 2032Patent 11229661
  • 26 October 2032Patent 10512657
  • 26 October 2032Patent 12350267
  • 12 February 2040Patent 11497745
  • 12 February 2040Patent 11229647
  • 5 October 2043Patent 12296050 drug product

Solution, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Livmarli. No generic is listed as marketed.

2020202520302035204001brand 2021data datePatent 11260053 listed to expire 26 May 2031Patent 10512657 listed to expire 26 October 2032Patent 11229661 listed to expire 26 October 2032Patent 11376251 listed to expire 26 October 2032Patent 12350267 listed to expire 26 October 2032Patent 11918578 listed to expire 12 February 2040Patent 11229647 listed to expire 12 February 2040Patent 11497745 listed to expire 12 February 2040Patent 12599602 listed to expire 12 February 2040Exclusivity I-938 to 13 March 2027Exclusivity ODE-379 to 29 September 2028Exclusivity ODE* to 29 September 2028Exclusivity ODE-429 to 13 March 2030Exclusivity ODE* to 13 March 2030Exclusivity ODE-471 to 13 March 2031Exclusivity ODE* to 13 March 2031Exclusivity ODE-490 to 24 July 2031
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 13 March 2027Exclusivity I-938 Livmarli
  • 29 September 2028Exclusivity ODE-379 Livmarli
  • 29 September 2028Exclusivity ODE* Livmarli
  • 13 March 2030Exclusivity ODE-429 Livmarli
  • 13 March 2030Exclusivity ODE* Livmarli
  • 13 March 2031Exclusivity ODE-471 Livmarli
  • 26 May 2031Patent 11260053
  • 26 October 2032Patent 10512657
  • 26 October 2032Patent 11229661
  • 26 October 2032Patent 11376251
  • 26 October 2032Patent 12350267
  • 12 February 2040Patent 11918578
  • 12 February 2040Patent 11229647
  • 12 February 2040Patent 11497745

1 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.